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ABSTRACT 
HLA-B*27 is strongly associated with an inflammatory autoimmune disorder, the Ankylosing 
Spondylitis (AS) and plays a protective role in viral infections. The two aspects might be linked. 
In this work, we compared in B*2705/B*07 positive patients with AS, the CD8+ T cell 
responses to two immunodominant EBV-derived epitopes restricted for either the HLA-B*27 
(pEBNA3C) or the HLA-B*07 (pEBNA3A). We have unexpectedly found that the HLA-B*07-
restricted EBNA3A peptide is presented by both the B*0702 and the B*2705 but not by the non 
AS-associated B*2709, that differs from the AS-associated B*2705 for a single amino acid in 
the peptide-binding groove (His116Asp). We then analysed 38 B*2705-positive/B*07-negative 
(31 AS-patients and 7 healthy donors) and 8 B*2709-positive/B*07-negative subjects. 
EBNA3A-specific CD8+ T lymphocytes were present in 55.3% of the HLA-B*2705 but in 
none of the B*2709 donors (p=0.0049). TCR β-chain analysis identified common TCRBV and 
TCRBJ gene segments and shared CDR3β sequences in pEBNA3A-responsive CTLs of 
B*2705 carriers, suggesting the existence of a shared TCR repertoire for recognition of the 
uncanonical B*2705/pEBNA3A complex. These data highlight the plasticity of the AS-
associated HLA-B*2705, which presents peptides with suboptimal binding motifs, possibly 
contributing both to its enhanced capacity to protect against pathogens and to predispose to 
autoimmunity.  
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INTRODUCTION 
In the context of the adaptive immunity, HLA class I-restricted CD8+ cytotoxic T 
lymphocytes (CTL) are pivotal in controlling viral infections. They express αβ T-cell receptors 
(TCRs) recognizing short viral antigens that are presented on the infected cells in association 
with HLA encoded class I heavy chain and β2-microglobulin. 
A major role of HLA-B alleles in mediating the most effective antiviral immunity has 
been reported (1, 2). However, not all HLA-B alleles are equally protective and some, such as 
the HLA-B*27 and -B*57, rank at the top given their superior capacity of viral control (3-5). 
Our understanding of their association with a slow progression to AIDS (4, 5) and with a 
high rate of spontaneous clearance of hepatitis C virus is still incomplete (6, 7). So far, either 
virological or immunological mechanisms have been postulated. Viral escape from HLA-B*27-
restricted CTL responses directed against HIV- and HCV-immunodominant epitopes is unlike 
since it requires several and compensatory mutations to overcome structural and functional 
constraints, with high costs for the viral fitness (7-9). On the other hand, a number of 
immunological factors shape the virus-specific, HLA-B*27-restricted CTL responses including 
polyfunctionality, superior functional avidity, selection of specific TCR clonotypes associated 
with a higher cross-reactivity, lower sensitivity to regulatory T cell-mediated suppression as 
well as a rapid and efficient processing of the proper epitopes (2, 6, 10-13). Another aspect to 
consider is the level of promiscuity within the same or different supertypes (14). Few studies 
have extensively and systematically approached this topic (15, 16). In addition, discordant 
results make difficult to determine whether epitope promiscuity by two or more HLA-B class I 
molecules is frequent (95% in ref (15)) or relatively uncommon (3% in ref (16)). HLA-B*27 
and -B*57 have been correlated to a more "private" peptide repertoire (82% and 56%, 
respectively) in comparison to other HLA class I alleles (14) suggesting that a low degree of 
promiscuity has protective effects. Overall, these data indicate that HLA-B*27 and -B*57 
alleles rarely share their own peptidome with other HLA molecules. Whether these alleles bind 
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and present immunodominant peptides restricted by other HLA-class I molecules has never 
been convincingly explored. 
Noteworthy, both HLA-B*27 and -B*57 family of alleles are associated with the 
susceptibility to autoimmune diseases, namely Ankylosing Spondylitis (AS) and Psoriasis, 
respectively (17-20). Therefore, it is conceivable that a common ground underlies the superior 
viral immune defence on the one hand and the propensity to autoimmunity on the other. The 
antigen presentation performed by such HLA-B supertypes could be a key event (7, 21). A way 
to validate this hypothesis could be a functional comparison between very close pair of alleles, 
like as the B*2705 and the B*2709, which have a single amino acid substitution (Asp116His) 
(22) but are differently associated with AS (19, 23-25). 
Here, we show that the B*2705, but not the non-AS-associated HLA-B*2709, presents an 
EBV-derived immunodominant epitope (pEBNA3A; RPPIFIRRL) restricted by the HLA-
B*0702 (26, 27) and therefore devoid of the optimal B*27 binding motif, evoking a vigorous 
CD8+ T cell response in B*2705/B*07-double positive as well as in B*2705-single positive 
carriers, either AS-patients or healthy donors (HD). The occurrence of preferential TCRBV and 
TCRBJ gene segments and the sharing of similar CDR3β regions by the B*2705-restricted 
pEBNA3A-responsive CTLs support the involvement of the TCR in such recognition.  
 
MATERIALS AND METHODS 
 
Study subjects 
 Four HLA-B*07/B*2705-double positive AS-patients, thirty-eight HLA-B*2705-
positive subjects (thirty-one AS-patients and seven HD) and eight HLA-B*2709-positive 
controls were enrolled in this study. Diagnosis of AS has been made according to modified 
New York criteria. The HLA-B*27 subtype was determined by serological analysis using ME1 
mAb (specificity: HLA-B*27; -B*07; -B*42; -B*67; -B*73 and -B*w22) and genomic analysis. 
The positivity to HLA-B*07 was checked by BB7.1 (specificity: HLA-B*07). The study 
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received the approval by the Ethics Committee of the University of Cagliari (365/09/CE). All 
subjects provided written informed consent prior to enrolment. 
Synthetic peptides and chimeric protein  
 pEBNA3C (RRIYDLIEL; aa 258-266) and pEBNA3A (RPPIFIRRL; aa 379-387) which 
are immunodominant EBV-epitopes restricted by HLA-B*27 (28) and by HLA-B*07 (26, 27) 
respectively, have been used in this study. For the binding assay, a self-peptide restricted by 
HLA-B*27 (TIS, RRLPIFSRL) (29) and an immunodominant CMV-epitope HLA-A*02-
restricted (pp65, NLVPMVATV) were included. A modified version of pEBNA3A 
(APPIFIRRL) has been also analysed. Peptides (purity >95%) were purchased by Aurogene 
(Rome, Italy). The chimeric protein containing EBNA3A epitope was generated using pTAT-
HA expression vector according to the procedure already described (30). To generate the 
EBNA3A epitope, the following primers have been used:  
forward: 5’-caag tactcgagaactgagaagcaggccaccaatattcataaggaggctgaga-3’;  
reverse: 5’-ccgaggaggccctctgttgattggtgt tccctccacttctcagcctccttatgaatat-3’. 
Following DNA sequencing of the recombinant construct, the production, purification and 
detection of the chimeric protein have been done as previously described (31). 
Cell lines  
 TAP-defective CEM 174.T2 cells (ATCC number: CRL-1992™) (32) and HMy2.C1R 
cells (ATCC number: CRL-1993™) (33), stably expressing B*2705, B*2709 (T2 and C1R 
cells) or B*0702, A*0201 (C1R cells) were used. C1R.B*0702 transfectants were a gift from 
Dr. J.A. Lόpez De Castro. 
Autologous B lymphoblastoid cell lines (B-LCLs) were generated by in vitro B cell 
immortalization with the standard type I EBV isolate B95.8 (22). 
Cells were cultured in heat-inactivated 10% fetal bovine serum (FBS; Sigma Aldrich, Saint 
Louis, Missouri, USA)/RPMI 1640 medium (Euroclone Spa, Pero, Mi, Italy) supplemented 
with 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin.  
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C1R and T2 stable transfectants were maintained in medium added with G418 (800 μg/ml) or 
hygromycin B (200 µg/ml), respectively. 
PBMC stimulation  
 PBMC (4x106) separated from whole blood by density gradient separation (Cedarlane 
Laboratoires limited, Hornby, Ontario, Canada) were incubated with the indicated peptides (20 
μM) and cultured for 12 days at 1.5x106 cells/ml in 5% FBS/RPMI complete medium, and 10 
U/ml of human recombinant interleukin 2 (IL2) (Roche Applied Science). On day 3 and 9, 
fresh medium containing 20 U/mL of IL2 was replenished. After 12 days of antigen pulsing, 
PBMC were used for pentamer staining and, on day 14, used for intracellular IFNγ staining. 
Pentamer staining  
 B*0702/pEBNA3A and B*2705/pEBNA3C MHC class I pentamers phycoerythrin-
conjugated were purchased by Proimmune (Oxford, United Kingdom). Twelve days after 
peptide stimulation, 0.5x106 PBMCs were treated with pentamers for 10’ at RT. Cells were 
then labelled with anti-CD8-FITC (mouse anti-human CD8-FITC-conjugated, BioLegend, San 
Diego, CA, USA) for 20’ on ice. The samples were acquired by a FACSCalibur flow cytometer 
(Becton Dickinson) and analysed by FlowJo software (Tree Star Inc.). 
Intracellular IFNγ staining  
 Briefly, C1R transfectants were incubated ON with pEBNA3A or pEBNA3C (30 μM) 
or with medium alone and then plated with antigen-stimulated PBMC at 5:1 PBMC/APC ratio. 
After 2h, the cells were treated with brefeldin A (10 μg/ml) at 37°C for 16h. Cells were stained 
with the anti-CD8-FITC mAb, 20’ on ice, fixed with 4% paraformaldehyde 20’ on ice, 
permeabilized with 1% BSA/0.1% saponin in PBS 1x for 5’ at RT and then resuspended in 2% 
paraformaldehyde/1% BSA.  Finally, cells were stained by an anti-IFNγ-APC mAb 
(BioLegend) 20’ RT and analyzed by FlowJo software.   
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CTL generation 
 PBMC were stimulated with pEBNA3A or pEBNA3C (30 μM) in 5% FBS/RPMI 1640. 
After 24h, PBMC were washed and 10 U/ml of IL2 were added to the culture medium. On day 
10, PBMC were depleted of the CD4+ T cell fraction by Dynabeads M-450 CD4+ (Dynal ASA, 
Oslo, Norway) and the isolated CD8+ T cells were seeded at 1×105 cells/well in 96-well plates 
in the presence of antigen-pulsed (overnight at 30 μM), γ-irradiated (200 Gy) autologous B-
LCLs (CD8+ T cells/APC ratio 2:1) and 20 U/ml of IL2. After 3 rounds of stimulation, cell 
antigen specificity was assayed in a standard 51Cr-release assay as previously described (34). 
TCR gene usage analysis  
 Total RNA was isolated from CD8+ T cells using the Trizol reagent (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturer’s instructions. Purified RNA was reverse-
transcribed using the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems). 
cDNA was used to amplify the TCRBV family chains with 24 TRBV specific primers as 
already described (35). Specific products were purified from gel (QIAquick, Qiagen spa, Italy) 
and underwent direct sequencing. The IMGT nomenclature has been adopted for TCRBV (36). 
T2.B*27 stabilization assay  
 ME1 mAb and an IgG1 isotype control antibody were employed to assess the capability 
of the peptide under study to stabilize the cell surface B*2705 or B*2709 molecules on T2 
transfectants (32) according to the procedure previously described (34). 
Statistics  
 Data obtained by IFNγ-production assays from antigen-stimulated PBMCs from 
B*2705-positive versus B*2709-positive carriers were compared by Fisher’s two-tailed exact 
test (figure 3C) and Mann-Whitney U-test (supplementary figure S3). A p value <0.05 was 
considered statistically significant. 
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RESULTS 
Atypical antigen presentation by HLA-B*2705 molecules  
 Our initial aim was to compare the immunological properties of HLA-B*2705-restricted 
versus HLA-B*0702-restricted CTLs. These two HLA class I alleles share 94% homology; 
nonetheless, the B*2705 is strongly AS-associated while the B*0702 plays a protective role 
(37). To overcome the inter-individual variability, we selected, a B*2705/B*0702-double 
positive patient with AS (Don 1.05.07). Freshly isolated PBMC were incubated with 
pEBNA3C or pEBNA3A, that are well known EBV-derived immunodominant epitopes 
restricted by HLA-B*2705 (28) or HLA-B*0702 (26, 27), respectively. CD8+ T cells specific 
for both epitopes were present, as assessed using B*2705/pEBNA3C and B*0702/pEBNA3A 
pentamers (0.265% for pEBNA3C- and 0.826% for pEBNA3A-reactive cells) (figure 1A).  
After 14 days, antigen-stimulated cells were re-exposed to the epitopes by co-culture with 
the peptide-pulsed C1R.B*0702, C1R.B*2705 or C1R.B*2709 transfectants and IFNγ-
production was measured in the CD8+ T cell fraction. Figure 1B shows that pEBNA3C-
exposed PBMCs were activated, as expected, only by pEBNA3C-prepulsed C1R.B*2705 and 
C1R.B*2709 cells, whereas no IFNγ-producing cells were detected when pEBNA3C-loaded 
C1R.B*0702 were used as control. In contrast, pEBNA3A-stimulated PBMCs produced IFNγ 
either when pEBNA3A was presented by either C1R.B*0702 cells (1.84% of IFNγ-producing 
CD8+ T cells) or C1R.B*2705 transfectants (2.9% of IFNγ-producing CD8+ T cells) but not 
when presented by C1R.B*2709 transfectants (figure 1B). To further explore this unexpected 
finding, the cytotoxic activity of pEBNA3A-stimulated cells against C1R transfectants was 
verified. Cytotoxicity occurred upon presentation of pEBNA3A by HLA-B*0702 and B*2705 
but not by B*2709 (figure 1C). In parallel, we tested pEBNA3C-specific CTL lines which, as 
expected, lysed both the C1R.B*2705 and C1R.B*2709 transfectants but not the HLA-B*0702 
(figure 1C). The pEBNA3A- and pEBNA3C-responsive CTL lines, although oligoclonal, did 
not display reciprocal cross-reactivity (data not shown). To exclude that the atypical 
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presentation B*07 restricted epitopes by HLA-B*27 molecules was an occasional event, three 
more B*2705/B*07-double positive individuals were analysed. Data from two other AS-
patients, Don 2.05.07 and Don 3.05.07 (figure 2 and supplementary figure S1, respectively) 
were consistent with the previous results. The fourth patient (Don 4.05.07) did not respond to 
pEBNA3A antigen either in B*07 or in B*27 context of presentation (data not shown). The 
results indicate that the promiscuous presentation of B*07 epitope is a common feature, 
occurring in 3/4 of the AS-patients analyzed. Moreover, it is selective for the AS-associated 
B*2705 molecule, since it is not shared by the closely related, non-disease associated B*2709.  
We have previously characterized an alternative antigen presentation pathway exploited 
by HLA-B*27, based on the use of intracellularly targeted chimeric proteins carrying viral 
epitopes (30, 31). We asked whether pEBNA3A could be presented by HLA-B*27 through this 
endogenous pathway. Accordingly, C1R.B transfectants were transduced by the chimeric 
protein harbouring the pEBNA3A sequence (figure 2B) and used as targets of pEBNA3A-
stimulated CTLs in cytotoxicity assays. Again, the pEBNA3A-chimeric protein made both 
C1R.B*0702 and C1R.B*2705 transfectants susceptible to specific lysis whereas neither 
C1R.B*2709 or C1R.A*0201 could present the epitope (figure 2C). 
 A possible explanation for the discordant behaviour of B*2705 and B*2709 could reside 
in a different binding affinity. However, available MHC binding prediction tools 
(http://www.cbs.dtu.dk/services/Net MHCcons/) failed to identify any binding for pEBNA3A 
to either B*27 allele. Stabilization assays on T2.B*2705 or T2.B*2709 transfectants (32) 
incubated with increasing amount of pEBNA3A, or TIS as positive reference (29), confirmed 
no detectable binding of pEBNA3A to B*27 alleles (supplementary figure S2).  
B*2705- but not B*2709-positive carriers elicit pEBNA3A-driven CD8+ T cell reactivity  
 The results obtained in three out of four B*07/B*2705-double positive individuals 
clearly indicated a promiscuous presentation of pEBNA3A. We therefore asked whether this 
epitope could elicit a specific T cell response in B*2705-positive/B*07-negative individuals.  
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PBMC from 38 HLA-B*2705-positive donors (31 patients with AS and 7 HD) were propagated 
in the presence of pEBNA3A. Following re-stimulation by pEBNA3A-pulsed C1R 
transfectants, antigen-specific IFNγ-production was measured. The results from one 
representative B*2705-positive individual (Don 10.05) revealed the presence of IFNγ-
producing CD8+ T cells (0.899%) when the peptide was presented by B*2705 but no by 
B*2709 or B*0702 molecules (figure 3A). A parallel stimulation with pEBNA3C yielded an 
expansion of IFNγ-producing CD8+ T cells in the B*27 context of presentation (1.05% by 
B*2705 and 1.38% by B*2709 allele).  The representative B*2709 individual (Don 6.09) did 
not respond to pEBNA3A while displaying reactivity towards pEBNA3C presented by either 
B*2705 or B*2709 (figure 3A).   
Cytotoxicity assays performed with pEBNA3A- and pEBNA3C-specific CTLs mirrored 
the results obtained by intracellular IFNγ staining (figure 3B). Twenty-one B*2705 carriers (18 
AS-patients and 3 HD) out of 38 were found pEBNA3A-responsive (55.3%) exclusively in the 
B*2705 context. On the contrary, none of the eight B*2709 individuals analysed showed 
pEBNA3A-reactivity making significant the difference between B*2705- and B*2709-positive 
EBNA3A responders (p=0.0049) (figure 3C). Functional data obtained by intracellular IFNγ 
staining after pEBNA3A stimulation in all B*2705 and B*2709 carriers analysed are shown in 
supplementary figure S3. Thus, pEBNA3A could be efficiently presented by B*2705 molecules 
and the repertoire of B*2705-positive individuals, independently of the disease, comprises 
CD8+ T cell precursors triggered by the non-canonical pEBNA3A/B*2705 complex. The same 
does not occur in the B*2709 context of presentation.  
To evaluate the functional avidity of pEBNA3A-specific CD8+ T cells of B*2705-
positive/B*07-negative subjects, PBMC were expanded in presence of pEBNA3A or 
pEBNA3C, and analysed in a dose-response intracellular IFNγ staining test upon re-stimulation 
with C1R.B*2705 transfectants. Figure 4A shows representative data obtained from an AS-
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patient (Don 15.05): at the higher peptide concentrations (3 and 30 µM), the percentage of 
IFNγ-secreting CD8+ T cells is greater for pEBNA3A than for pEBNA3C (5.74% vs 3.42% 
and 3.29% vs 2.7%, respectively). This trend reversed at the lowest peptide concentration (0.3 
µM) (0.37% vs 2.1%) but yet, the detection of some pEBNA3A-responsive CD8+ T cells 
suggested that these virus-specific CTLs have a comparable functional avidity. These data have 
been further validated by cytotoxicity assays performed on these same cells following CD8+ T 
cell purification. Once again, at higher antigen concentrations (range 0.3-30 µM), specific lysis 
was greater for pEBNA3A- than pEBNA3C-stimulated CTLs (figure 4B) while the opposite 
occurred at the lowest concentration (0.03 µM).  
To understand whether the N-terminal Arg in pEBNA3A acts as principal anchor fitting 
into the B-pocket, we tested a modified version of the peptide with pAla1 instead of pArg1. 
Functional data by EBNA3A-stimulated PBMC from a B*2705-positive patient with AS (Don 
31.05) displayed substantially no production of IFNγ upon re-activation by C1R.B*2705 pulsed 
by the modified peptide pAla1-EBNA3A at increasing peptide concentrations (Figure S4). This 
result was replicated by PBMCs from other two B*2705-positive patients with AS (data not 
shown). 
Identification of shared TCR β-chain motifs implicated in B*2705/pEBNA3A and 
B*0702/pEBNA3A complex recognition  
 We then verified whether common TCR β-chain motifs were used to recognize 
pEBNA3A either in association with B*2705 or B*07. The analysis was performed on 
repeatedly antigen-stimulated CD8+ T cell lines (4-5 rounds of stimulation) that, although 
oligoclonal, were highly enriched for pEBNA3A-specific T cells. The assessment was 
conducted on four B*2705 carriers, two B*2705/B*07 subjects and three B*07-positive donors 
which were strongly pEBNA3A-reactive. For each subject, only the most abundantly expressed 
TCRBV chains underwent direct sequencing and a further selection was made to retrieve only 
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unambiguous signals. Table 1 reports the most relevant sequences. T cells from two B*2705 
AS-patients (Don 10.05 and Don 1.05) shared an almost identical TCR β-chain (TRBV24-
1TRBJ2-1) with a single difference from Ser(S) to Gln(Q) in the CDR3 region (DLGS/QGVG). 
A similar TCR β-chain sequence was also expanded in T cells of a third B*2705 AS-patient 
(Don 17.05) showing an homologous CDR3 motif (DMGQN), a same BJ2-1 segment but BV4-
1 instead of the BV24-1. Noteworthy, the BV4-1 segment was used by the public TCR β-chain 
(TRBV4-1TRBJ2-7) found in CTLs of a B*2705/B*07 AS-patient (Don 1.05.07) as well as in 
a B*07-positive HD (Don 2.07) and thus, presumably, selected as interacting with the canonical 
B*07/pEBNA3A complex. Consistent with these findings, we retrieved TCR β-chains similar 
to the previous one, bearing the same BV4-1 and CDR3 motifs, from two other B*07-positive 
HD (Don 3.07 and Don 4.07). It is noteworthy that almost all reported sequences have a 
negatively charged amino acid (D or E) in the CDR3 region.  
 
DISCUSSION 
This study addresses the question whether the immunological mechanisms whereby 
HLA-B*27 is protective against viruses could overlap with those that make it strongly 
associated with autoimmunity. In spite of overwhelming data, the pathogenic role/s of HLA-
B*27 in AS and related Spondyloarthritis remains uncertain (19).  
Our findings show that an EBV-derived epitope immunodominant in the HLA-B*07 
context, although lacking of an optimal B*27 binding motif, is presented by the HLA-B*2705 
but not by the non-AS-associated B*2709 allele (17-19, 23, 24). Such atypical presentation by 
B*2705 evokes T cell-specific responses comparable in magnitude to those elicited by 
pEBNA3A presentation on B*07. It is therefore conceivable that during an EBV infection, 
HLA-B*07 and HLA-B*2705 could actively cooperate or even compete for this same epitope. 
Noteworthy, it has been recently shown that HLA-B*07 plays a protective role in AS (37). Our 
data allow to speculate that, in an HLA-B*2705 context, the co-presence of HLA-B*07 could 
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play a favourable role subtracting “pathogenic” epitopes to HLA-B*27 (18, 25). Conversely, it 
is questionable whether this epitope sharing is beneficial or detrimental to the antiviral 
immunity. This aspect would deserve further investigation in view of a vaccine design (38). 
A further question is whether distinct CTL populations do exist, each recognizing 
pEBNA3A in a specific HLA context. Alternatively cross-reactive antigen-specific T cells 
could mediate the response. In this respect, in a B*07/B*2705-positive AS-patient (Don 
2.05.07), we monitored, along the time, the cytotoxicity of pEBNA3A-stimulated CTLs that 
lost the capacity to kill pEBNA3A-pulsed C1R.B*0702 but not C1R.B*2705 targets (data not 
shown). This suggests the existence of CTLs with distinct specificities and a higher capacity of 
B*2705-restricted, pEBNA3A-responsive CTLs to survive. Presumably, a lower functional 
avidity of these CTLs decreases their susceptibility to exhaustion and activation-induced cell 
death (2, 39). 
Noteworthy, pEBNA3A-driven CD8+ T cell reactivity has been found in 55.3% B*2705-
positive subjects analysed and none of the B*2709 donors consistently with a sizeable event 
independent from the HLA-B*07.  
Therefore, whilst in B*07/B*2705-positive individuals, the effect of the promiscuous 
presentation is unclear, in B*2705-positive/B*07-negative subjects the existence of long-lived 
pEBNA3A-responsive B*2705-restricted T cells would confer a net advantage on viral control. 
A further immunological basis for the enhanced protection of B*27 could be its engagement in 
a number of productive antiviral responses far greater than expected and characterised by a 
wide spectrum of functional avidities. Intriguingly, these data are consistent with a case of 
allele-dependent epitope promiscuity in which being a risk factor to autoimmunity parallels 
with an enhanced anti-viral immune response (7, 17-19, 21).  
Several studies have showed that epitope binding affinity is not an absolute predictive 
factor for the strength and frequency of T cell responses (3, 39). Paradoxically, predictive 
algorithms and stabilization experiments failed to show any pEBNA3A binding to B*2705 or 
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B*2709 molecules. However, computational data indicated a higher number of hydrogen bonds 
lost by pEBNA3A/B*2709 compared to pEBNA3A/B*2705 complex during a 20 ns molecular 
dynamics simulation, hinting for a more loosely embedding of the peptide on the B*2709. 
Moreover, the pEBNA3A/B*2709 complex had a higher fluctuation in the α2-helix (residues 
170-189) suggesting a higher entropic cost for TCR to interact with such complex (Prof. Rainer 
Böckmann, personal communication).  Overall, although pEBNA3A is apparently a poor B*27 
binder, nevertheless B*2705 but not B*2709 should be capable to form a complex stable 
enough to induce a CTL response. This is supported by the absence of pEBNA3A-specific 
CTLs in B*2709-positive individuals, by the lack of allo- and cross-recognition to pEBNA3A-
B*2709 complexes in either B*07/B*2705- or B*2705-positive donors. 
An obvious question is how pEBNA3A can fit into the B*2705 groove although devoid 
of pArg2, the B*27 dominant anchor residue (40, 41). The presence of a pArg1 might allow the 
fitting into the B-pocket as strongly suggested by the abrogation of cell activation when the N-
terminal Arg was replaced by an Ala. Accordingly, a comparable configuration was previously 
described by X-ray crystallography of an octameric peptide accommodating itself into the 
HLA-A2 groove leaving the A-pocket empty and prone to stabilization by water molecules (42). 
Very recently, the characterization of Behçet's disease-associated B*5101 peptidome revealed 
that major peptide motifs are pPro2 or pAla2 (43). Interestingly, beside the canonical nonamers 
and, more rarely, decamers with pPro2 or pAla2, the peptide elution analysis showed the 
presence of N-terminal truncated versions with pPro1 or pAla1. For these peptides, it is 
conceivable a non-canonical binding mode with the P1 residue occupying the B-pocket. 
pEBNA3A has a C-terminal Leu often found, as PΩ anchor, in the B*2705 peptidome but even 
more frequently in that of B*2709 (40, 41). However, the presence in pEBNA3A of two Arg 
preceding pLeu9 could favour the peptide stabilization in the F-pocket of B*2705 by direct or 
indirect interactions with Asp116. This would be not allowed for B*2709 possessing His116. 
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EBNA3A epitope has a proline at P2 (pPro2). Noteworthy, the endoplasmic reticulum 
aminopeptidase 1 and 2, ERAP1 and ERAP2, which trim N-terminally extended peptides into 
the ER, display a poor ability to cleave X-Pro bonds thus creating a considerable pool of 
peptides with pPro2 (44). Many HLA-B/C alleles bind pPro2 peptides, generated only into the 
ER by ERAP1 and ERAP2 processing since TAP molecules barely translocate them (44, 45).  
Hence, the available amount of peptides such as pEBNA3A is heavily influenced by ERAP1 
and ERAP2 enzymatic activity. ERAP1 is the second stronger gene associated with AS-
susceptibility and the risk allelic variants are enzymatically more active than the protective ones 
(46-48). It must be considered that the association of ERAP1 with AS has been found only in 
B*27-positive patients, consistent with disease models in which an aberrant ERAP1 trimming 
and/or HLA-B*27 presentation to CD8+ T cells are involved in HLA-B*27-associated disease 
pathogenesis (46, 48).  
On CD8+ T cells, HLA-B*27, as classical trimeric complex, could be engaged by TCR as 
well as by innate immune receptors, such as KIR or LILR, but in the latter case it is unclear 
whether specific peptides are required (18). However, in our system, the TCR involvement is 
strongly supported by the shared TRBV24-1TRBJ2-1 usage and by an almost identical CDR3β 
expressed by pEBNA3A-responsive CD8+ T cells from B*2705 AS-patients. Furthermore, 
other TCRs from B*2705-restricted pEBNA3A-responsive CTLs are characterized by the 
TRBV4-1 segment usage in common with CTLs recognizing pEBNA3A in the B*07 context of 
presentation. It should be noticed that the majority of TCR β chains selected bona fide for 
recognition of pEBNA3A either in complex with B*07 or with B*2705, display an acidic 
amino acid (Asp or Glu) in the CDR3β region. Hence, it is likely that one of the two Arg, in P7 
or in P8, depending on the positioning of Arg P1 whether in A or B pocket, could be fully 
accessible to TCR, acting as docking site that selects CDR3β sequences having negative charge. 
Conversely, the N-terminus of peptide mainly contacted by the TCR α-chain could not exert 
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the same imprinting effect and, consequently, from the TCR α-chain repertoire of pEBNA3A-
responsive CTLs, no shared motifs emerged (data not shown). 
 
CONCLUSION 
Taken together, these data disclose the capability by B*2705 to behave as restriction 
element for a peptide discharged as binder by all algorithms but abundantly produced when 
ERAP1 is enzymatically fully active. This strong flexibility of B*2705 groove anticipated by 
biophysical methods and computational analysis (21, 49, 50) and here reinforced by T-cell 
functional data must be regarded as a key feature for its enhanced ability to mediate viral 
protection and for association with autoimmunity. 
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              Table 1. 
 
TCR β-chain sequences of pEBNA3A-responsive CTL lines 
Donor TRBV CDR3 TRBJ 
Pt B*27 (Don 10.05) 24-1 CATSDLGSGVGNEQF 2-1 
Pt B*27 (Don 1.05) 24-1 CATSDLGQGVGNEQF 2-1 
Pt B*27 (Don 17.05) 4-1 CASSQDMGQNNEQF 2-1 
Pt B*27/B*07 (Don 1.05.07) 4-1 CASSQETGSYEQY 2-7 
HD B*07 (Don 2.07) 4-1 CASSQETGSYEQY 2-7 
HD B*07 (Don 3.07) 4-1 CASSQEGGTATYEQY 2-7 
HD B*07 (Don 4.07) 4-1 CASSQETGIHTQY 2-3 
Pt B*27 (Don 10.05) 4-1 CASSQDGAGGSTDTQY 2-3 
Pt B*27 (Don 15.05) 18 CASSEGQVPSKEQF 2-7 
Pt B*27 (Don 15.05) 2 CASSEDGENTDTQY 2-3 
Pt B*27 (Don 10.05) 6-1 CASSEGAGGSYNEQF 2-1 
Pt B*27/B*07 (Don 2.05.07) 3-1 CASSLGTDTQY 2-3 
Pt, patient with AS; HD, healthy donor.  
The IMGT nomenclature has been used (36).     
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FIGURE LEGENDS 
 
Figure 1.  B*2705 can promiscuously present the B*0702-restricted EBNA3A epitope to CD8+ 
T cells from a B*2705/B*0702 positive AS patient (Don 1.05.07). (A) Flow cytometry plots for 
HLA-B*2705/pEBNA3C (left panel) and HLA-B*0702/pEBNA3A (right panel) pentamer 
staining within CD8+ T cells of PBMCs cultured for 12 days with pEBNA3C and pEBNA3A 
synthetic peptides (20 µM), respectively. Numbers indicate the percentage of pentamer-positive 
CD8+ T cells. Smaller panels show flow cytometry profiles of pEBNA3C- (left) or pEBNA3A-
stimulated (right) PBMCs for staining with an irrelevant pentamer. (B) Detection of intracellular 
IFNγ production by PBMCs stimulated with pEBNA3C or pEBNA3A for 14 days and then re-
stimulated by the indicated, untreated or peptide-pulsed C1R transfectants (30 µM). Numbers 
represent the percentage of IFNγ-producing CD8+ T cells. (C) Assessment of cytotoxicity by 
representative pEBNA3A- (top) and pEBNA3C- (bottom) stimulated CTL lines against HLA-
B*0702, -B*2705, -B*2709 C1R transfectants used as target cells. E/T ratio was 20:1. Bars 
represent the mean percentage of specific lysis ± SEM of three separate experiments. 
Figure 2. Uncanonical pEBNA3A presentation by HLA-B*2705 in a second B*2705/B*07-
positive AS patient. (A) Measurement of IFNγ secretion in PBMCs from Don 2.05.07 stimulated 
with pEBNA3A for 14 days and then re-stimulated by untreated or pEBNA3A-pulsed C1R 
transfectants. Numbers represent the percentage of IFNγ-producing CD8+ T cells. (B) Schematic 
representation of the pEBNA3A-chimeric protein showing the location at the N-terminus of 6-
His tag, the TAT transduction domain and the hemoagglutinin (HA) tag followed by the 
nucleoprotein of influenza A virus protein in which the sequence of EBNA3A epitope has been 
inserted. (C) 51Cr-release assay in which cytolytic effector functions of a representative 
pEBNA3A-stimulated CTL line was tested against C1R transfected cells, pre-pulsed with 
pEBNA3A provided as synthetic peptide (30 µM) or transduced by the chimeric protein carrying 
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EBNA3A epitope (1 µM). E/T ratio was 20:1. Bars represent the mean percentage of specific 
lysis ± SEM of three separate experiments.  
Figure 3. B*2705 but not B*2709-positive carriers react towards the HLA-B*0702-restricted 
EBNA3A epitope. (A) Detection of intracellular IFNγ production by PBMCs from a B*2705 
positive/B*07 negative subject (Don 10.05) (left) or a B*2709 positive/B*07 negative subject 
(Don 6.09) (right) activated with pEBNA3A or pEBNA3C peptide for 14 days and then re-
stimulated by the indicated, untreated or peptide-pulsed C1R transfectants. Numbers represent 
the percentage of IFNγ-producing CD8+ T cells. (B) Cytotoxic activity by representative 
pEBNA3A- (top) and pEBNA3C- (bottom) stimulated CTL lines from the same individuals as in 
(A) towards C1R transfectants used as target cells. E/T ratio was 20:1. Bars represent the mean 
percentage of specific lysis ± SEM of three separate experiments. (C) CD8+ T cell responses to 
EBNA3A detected by IFNγ production analysed in 38 B*2705 carriers (31 patients with AS and 
7 healthy controls) and in 8 B*2709 healthy donors. Twenty-one out of 38 B*2705 and no 
subject out of 8 B*2709 individuals show reactivity against EBNA3A antigen (p value = 0.0049 
calculated by Fisher’s two-tailed exact test). 
Figure 4. Functional avidity compared between pEBNA3A- and pEBNA3C-specific CD8+ T 
cells from B*2705 donors. (A) Flow cytometry plots reporting IFNγ production by PBMCs from 
a representative B*2705 AS patient (Don 15.05) expanded in presence of pEBNA3A or 
pEBNA3C (14 days) and exposed to C1R.B*2705 transfectants pulsed with increasing 
concentrations of each peptide before intracellular staining. Numbers indicate the percentage of 
IFNγ-secreting CD8+ T cells. (B) Assessment of the cytolytic activity of representative 
pEBNA3A- and pEBNA3C-stimulated CTL lines from the same donor as in (A). C1R.B*2705 
transfectants pre-pulsed with serial amounts of the indicated peptide were used as targets. E/T 
ratio was 20:1. Bars represent the mean percentage of specific lysis ± SEM of three separate 
experiments. 
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FIGURE LEGENDS 
Figure S1. The promiscuous presentation of pEBNA3A by the HLA-B*2705 allele is not a 
sporadic event. pEBNA3A-reactivity in a third B*2705/B*07 positive patient with AS (Don 
3.05.07) evaluated by intracellular IFNγ detection. PBMCs incubated for 14 days with pEBNA3A 
were re-stimulated by untreated or pEBNA3A-pulsed C1R.B*0702, C1R.B*2705, C1R.B*2709 
transfected cells before intracellular IFNγ staining. Numbers represent the percentage of IFNγ-
producing cells in the CD8+ T cell population. 
 
Figure S2. Poor binding of pEBNA3A to B*2705 and B*2709 molecules. Reactivity of B*2705 
and B*2709 molecules expressed on the cell surface of T2 transfectants with ME1 mAb after 
incubation with pEBNA3A for 16 hours at indicated concentrations or with TIS peptide 
(RRLPIFSRL) used as positive reference or with an irrelevant peptide. Results are expressed as 
ratio between the mean fluorescence intensity (MFI) obtained with peptide treated and untreated 
cells. Values represent the mean ± SEM of three independent experiments. 
 
Figure S3. Magnitude of pEBNA3A-specific CD8+ T cell responses in B*2705-positive 
compared to B*2709-positive carriers. Cumulative data indicating the percentage of IFNγ-
producing CD8+ T cells in PBMC populations from 38 B*2705 positive individuals (31 patients 
with AS and 7 healthy donors) and from 8 B*2709 positive subjects cultured in presence of 
pEBNA3A for 14 days and then re-stimulated by pEBNA3A-pulsed C1R transfectants before 
intracellular IFNγ staining. Open circles indicate mock responses while filled circles represent 
pEBNA3A-specific responses since, arbitrarily, only % of IFNγ-producing CD8+ T cells greater 
than 0.1 have been considered as relevant. The statistical significance was assessed using Mann-
Whitney U-test (***p < 0.0001). 
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Figure S4. Ala substitution to pArg1 in EBNA3A peptide abrogates the activation of pEBNA3A-
responsive PBMCs derived from B*2705 positive carriers. Detection of intracellular IFNγ 
production by PBMCs from a representative B*2705-positive patient with AS  (Don 31.05) 
expanded in presence of pEBNA3A for 14 days and then re-exposed to C1R.B*2705 transfectants 
untreated or pulsed with increasing concentrations of pEBNA3A (left panels) or the modified 
version of pEBNA3A with pAla1 (right panels) before intracellular staining. Numbers indicate the 
percentage of IFNγ-secreting CD8+ T cells.  
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